NICE has recommended the first disease-modifying therapy for NHS use to delay the onset of type 1 diabetes, in a move the health body says could give eligible patients up to three extra years before the condition develops. The final draft guidance was published on 23 June 2026 and marks a notable step in the treatment of a disease that often begins in childhood or early adulthood.
The recommendation follows a period of assessment by NICE and places the therapy among the most closely watched recent developments in UK diabetes care. According to NICE, the treatment is now set to become available on the NHS for people at high risk of developing type 1 diabetes, offering what the organisation described as a first-of-its-kind approach.
A new option for delaying disease progression
Type 1 diabetes is a long-term condition in which the immune system attacks the cells that produce insulin. NICE said the newly recommended therapy can delay the onset of the disease for up to three years, giving patients and families additional time before daily insulin management becomes necessary.
The announcement comes just days after NICE published other high-profile guidance in oncology, including a new treatment option for recurrent or metastatic cervical cancer on 24 June 2026 and its earlier recommendation for women with resistant ovarian cancer on 4 June 2026. But the type 1 diabetes decision stands out as one of the most significant recent advances outside cancer care, because it introduces a disease-modifying option rather than a treatment that manages symptoms after diagnosis. ([nice.org.uk](https://www.nice.org.uk/news/articles))
Part of a busy month for NICE guidance
NICE’s news page shows a run of major announcements across June 2026, including guidance on an artificial pancreas device for pregnant women with type 1 diabetes, published on 3 June, and the latest diabetes recommendation published on 23 June. That sequence highlights how active the organisation has been in recent weeks as it continues to update NHS access to new technologies and medicines. ([nice.org.uk](https://www.nice.org.uk/news/articles))
For patients and clinicians, the new recommendation may also carry wider significance because it reflects a shift toward preventing or postponing disease progression in people identified early. NICE said the therapy is intended for NHS use and could alter the timeline of care for those at risk, although the guidance itself focuses on availability rather than detailing individual patient pathways. ([nice.org.uk](https://www.nice.org.uk/news/articles))
The latest decision adds to a broader pattern of rapid change in UK health policy, where regulators and advisory bodies are increasingly weighing earlier intervention, targeted treatment and more personalised pathways. In that context, the recommendation for type 1 diabetes is likely to be closely followed by clinicians, patient groups and health system planners in the months ahead. ([nice.org.uk](https://www.nice.org.uk/news/articles))
For now, the key message from NICE is clear: a first-of-its-kind therapy is on course for NHS availability, and for some people at risk of type 1 diabetes, that could mean years of extra time before the condition begins. ([nice.org.uk](https://www.nice.org.uk/news/articles))
